Genzyme's Pipeline Outlook

	Research	Preclinical	Phase 1	Phase 2	Phase 3	Postmarketing Studies
GENETIC DISEASE
Cerezyme product enhancements
Fabrazyme multiple studies
Genz-112638 small molecule Gaucher disease
Acid sphingomyelinase type B Niemann-Pick disease
Acid sphingomyelinase type A Niemann-Pick disease
Myozyme next generation
RENAL DISEASE
Renvela chronic kidney disease on dialysis
Renvela chronic kidney disease
Renvela powder formulation
GC1008 kidney sclerosis
Small molecule polycystic kidney disease
Genz - 644470 hyperphosphatemia
ORTHOPAEDICS AND BIOSURGICAL SPECIALTIES
Synvisc-One osteoarthritis pain relief
Hylastan (EU) new formulation
Sepraspray (EU) new formulation adhesion barrier
Next generation adhesion barrier
Next generation osteoarthritis pain relief
Next generation cartilage repair
ONCOLOGY
Campath chronic lymphocytic leukemia
Clolar pediatric acute lymphocytic leukemia
Clolar adult acute myeloid leukemia
Mozobil tumor sensitization
Thymoglobulin myelodysplastic syndromes
Clofarabine myelodysplastic syndromes
GC1008 solid tumors
ENDOCRINOLOGY
TSH nontoxic multinodular goiter
TRANSPLANT AND IMMUNE DISEASE
Mozobil stem cell mobilization
Alemtuzumab multiple sclerosis
Thymoglobulin living kidney donor
Thymoglobulin liver transplant
GC1008 pulmonary fibrosis
Hectorol psoriasis
Fc receptor antagonist idiopathic thrombocytopenic purpura
EARLY-STAGE PROMISE
Mipomersen LDL-C reduction
Gene therapy peripheral arterial disease
Clolar solid tumors
Gene therapy Parkinson's disease
Tasidotin solid tumors
Topoisomerase I inhibitors solid tumors
Gene therapy age-related macular degeneration
Genz - 642347 type 2 diabetes
Genz - 29155 solid organ transplant
Campath immune-mediated diseases